Learnings from the first AI-enabled skin cancer device for primary care authorized by FDA.
Venkatesh. Kaushik P KP; Kadakia. Kushal T KT; Gilbert. Stephen S
Key Findings
- DermaSensor is the first AI‑enabled skin cancer detection device cleared for use by primary‑care providers.
- The approval demonstrates that AI can help bridge gaps in expertise and access in dermatology.
- It creates a regulatory precedent for future AI/ML medical devices in skin care.
Practical Outcomes
- While this breakthrough is important for medical practice, it doesn’t provide direct, actionable steps for biohackers or N=1 experiments focused on longevity or performance.
Summary
The FDA has approved the first AI-powered tool that helps primary‑care doctors spot skin cancer, showing that AI can safely assist non‑specialists in diagnosing skin issues and setting a new regulatory path for similar devices.
Abstract
The U.S. Food and Drug Administration’s (FDA) recent authorization of DermaSensor, an AI-enabled device for skin cancer detection in primary care, marks a pivotal moment in digital health innovation. Clinically, the authorization of the first AI-enabled device for use by non-specialists for detecting skin cancer reinforces the feasibility of digital health technologies to bridge gaps in access and expertise in medical practice. The authorization also establishes a new regulatory precedent for FDA authorization of medical devices incorporating AI and machine learning (ML) technologies within dermatology. Together, this article uses the DermaSensor authorization to examine the clinical evidence and regulatory implications of emerging AI-enabled technologies in dermatology.
Study Information
pubmed
2024
2024-06-15T00:00:00.000Z
10.1038/s41746-024-01161-1
19
15